ArticleFrontiers in oncology2026
Surgery-based treatment and prognostic factors in patients with limited-stage small cell lung cancer: a retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Small cell lung cancer (SCLC) is an aggressive malignancy with poor prognosis, and the role of surgery in limited-stage disease remains controversial. This study evaluated the impact of surgery-based treatment for limited-stage SCLC (LS-SCLC) and identified prognostic factors. Methods: Clinical data of 103 highly selected patients who underwent complete R0 resection and perioperative adjuvant therapy at the Fourth Hospital of Hebei Medical University from 2014 to 2019 were retrospectively analyzed. Disease-free survival (DFS) and overall survival (OS) were assessed by Kaplan-Meier analysis, and independent prognostic factors were determined using multivariable Cox regression. Results: The cohort included 60 males and 43 females, aged 22-76 years, with a median follow-up of 64 months (IQR: 25-83 months). The median OS was 81 months, and the 5-year OS rate was 58.3%; the median DFS was 50 months, and the 5-year DFS rate was 50.5%. Patients with stage I-IIA disease had significantly better survival than those with stage IIB-IIIB (5-year OS: 69.2% vs. 47.1%, Conclusions: In this highly selected cohort, radical surgery followed by adjuvant chemotherapy and thoracic radiotherapy was associated with improved survival in LS-SCLC, particularly in stage IIB or higher disease. Given the absence of a non-surgical control group, these findings are hypothesis-generating and warrant prospective validation. Postoperative brain metastasis, as a post-treatment progression event, was associated with markedly poor outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.